Resource Logo
Reuters New Media

FDA approves GSK's HIV-1 drug


Aug 12 (Reuters) - The U.S. Food and Drug Administration approved Tivicay, GlaxoSmithKline Plc's drug targeted at HIV-1, the most common strain of the virus that causes AIDS.

The drug, known generically as dolutegravir, is intended to be taken daily in combination with other HIV drugs.

Tivicay, which interferes with one of the enzymes necessary for the virus to multiply, can be used to treat infected adults who have been treated with other drugs or are new to treatment.

The FDA also approved the use of the drug for children aged 12 years and over, who weigh at least 40 kilograms and who have not received treatment that has the same mechanism as the drug.

Tivicay was tested in adults in four clinical trials in combination with other antiretroviral drugs, and in one trial involving children.

The FDA's decision comes a few days after it approved Alere Inc's test for two types of HIV.


Copyright © 2013 -Reuters New Media, Publisher. All rights reserved to Reuters .Ltd. Republication or redistribution of Reuters content is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Information in this article was accurate in August 12, 2013. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.